Compugen Discovers Biomarker Candidate for Diagnosis of Ovarian Cancer and Signs Collaboration Agreement
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Compugen Ltd. has disclosed the discovery and experimental verification of CGEN-327, a novel molecular biomarker candidate for the diagnosis of ovarian cancer.
CGEN-327 is a previously unknown splice variant of the HE4 (Human Epididymis Protein 4) gene, which is a known biomarker for ovarian cancer. The company also announced that it has entered into a research and license option agreement for the product candidate with a leading diagnostic company. Patent coverage for this discovery is being pursued by Compugen.
Anat Cohen-Dayag, vice president of R&D for Compugen stated, “This is an excellent example of Compugen’s unique “discovery on demand” capabilities. In this case, we were approached by a leading company developing and commercializing immunoassay panels for rapid diagnosis of challenging diseases. Their specific interest was to determine whether any unknown splice variants exist for this known biomarker for ovarian cancer, an objective with a high level of industry interest and past research activity.”
The recently signed collaboration agreement provides Compugen’s partner with an option to obtain worldwide royalty bearing commercialization rights for diagnostic products based on this and novel gene product, with Compugen retaining all therapeutic applications. Financial terms were not disclosed.
CGEN-327 is a previously unknown splice variant of the HE4 (Human Epididymis Protein 4) gene, which is a known biomarker for ovarian cancer. The company also announced that it has entered into a research and license option agreement for the product candidate with a leading diagnostic company. Patent coverage for this discovery is being pursued by Compugen.
Anat Cohen-Dayag, vice president of R&D for Compugen stated, “This is an excellent example of Compugen’s unique “discovery on demand” capabilities. In this case, we were approached by a leading company developing and commercializing immunoassay panels for rapid diagnosis of challenging diseases. Their specific interest was to determine whether any unknown splice variants exist for this known biomarker for ovarian cancer, an objective with a high level of industry interest and past research activity.”
The recently signed collaboration agreement provides Compugen’s partner with an option to obtain worldwide royalty bearing commercialization rights for diagnostic products based on this and novel gene product, with Compugen retaining all therapeutic applications. Financial terms were not disclosed.
